Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Myelodysplastic syndrome is caused by mutation of one or more genes that control development of blood cells. It is one of the most common malignant hematological diseases that affects five out of every 100,000 people in U.S. annually. An estimated 60,000 people in U.S. live with MDS, and approximately 10,000-15,000 new cases are reported each year. Patients may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Exposure to chemicals (such as pesticides, tobacco, and benzene) and heavy metals (such as mercury and lead) may trigger disease onset.
In recent years, demand for hypomethylating agents has been at a high due to approval and adoption of Vidaza and Dacogen. A strong pipeline including Aranesp is expected to boost market growth in the near future. Easy availability of and access to novel treatments in major countries provides strong commercial opportunities to the market.
In 2018, the global Myelodysplastic Syndrome (MDS) Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Myelodysplastic Syndrome (MDS) Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myelodysplastic Syndrome (MDS) Drugs development in United States, Europe and China.
The key players covered in this study
Celgene
Amgen
Otsuka
Takeda
...
Market segment by Type, the product can be split into
Hypomethylating Agents
Immunomodulatory Drugs
Anti-anemics
Market segment by Application, split into
Original
Generics
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Myelodysplastic Syndrome (MDS) Drugs status, future forecast, growth opportunity, key market and key players.
To present the Myelodysplastic Syndrome (MDS) Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Myelodysplastic Syndrome (MDS) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
In recent years, demand for hypomethylating agents has been at a high due to approval and adoption of Vidaza and Dacogen. A strong pipeline including Aranesp is expected to boost market growth in the near future. Easy availability of and access to novel treatments in major countries provides strong commercial opportunities to the market.
In 2018, the global Myelodysplastic Syndrome (MDS) Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Myelodysplastic Syndrome (MDS) Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myelodysplastic Syndrome (MDS) Drugs development in United States, Europe and China.
The key players covered in this study
Celgene
Amgen
Otsuka
Takeda
...
Market segment by Type, the product can be split into
Hypomethylating Agents
Immunomodulatory Drugs
Anti-anemics
Market segment by Application, split into
Original
Generics
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Myelodysplastic Syndrome (MDS) Drugs status, future forecast, growth opportunity, key market and key players.
To present the Myelodysplastic Syndrome (MDS) Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Myelodysplastic Syndrome (MDS) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
